This website uses cookies to store information on your computer. Some of these cookies are used for visitor analysis, others are essential to making our site function properly and improve the user experience. By using this site, you consent to the placement of these cookies. Click Accept to consent and dismiss this message or Deny to leave this website. Read our Privacy Statement for more.
Print Page   |   Contact Us   |   Sign In   |   Register
Community Search
Higher Order Structure 2016
Share |

 
 

Monday, April 11, 2016 - Wednesday, April 13, 2016

Renaissance Long Beach Hotel, Long Beach, CA

 



5th International Symposium on Higher Order Structure of Protein Therapeutics


 

    

 

Thank you to all who attended and helped make Higher Order Structure 2016 a success!
Mark your calendars for HOS 2017: April 3-5, 2017 in Gaithersburg, Maryland. 

Protein higher order structure (HOS) includes the secondary, tertiary and quaternary structures of a protein, which comprise the three dimensional structures that are necessary for structure and function. Proteins in solution are dynamic molecules which can sample an ensemble of structures in solution, and have molecular properties which results in differing propensities to self associate and form a range of species from oligomers to visible particles. Changes in the HOS of proteins can  contribute to the quality attributes, and potentially safety, efficacy, and pharmacokinetic properties of protein therapeutica. Regulatory agencies require assessment of HOS to assess how protein structure is affected by manufacturing, storage and delivery; and analytical biosimilarity is an important part of evaluating potential changes in clinical safety and efficacy. There are many biophysical characterization methods and tools used in monitoring the attributes of protein therapeutics such as conformation and higher order structure.  However, since most biophysical analyses provide ensemble average structural information of the molecules, it is essential to evaluate if the observed changes are significant and are tracking changes in CQAs, and cannot be attributed to assay or process variability. Use of the appropriate biophysical method, method development and qualification to characterize the quality attributes at different stages of the product lifecycle are therefore a matter of interest and debate for a wide range of audiences. This Symposium will focus on various biophysical methods for assessment of protein HOS, as well as the applications of the appropriate tools during the different stages of protein therapeutic development and biosimilarity assessments, the theory and practice of biophysics, technical data from academia and industry as well as method qualification, validation and setting specifications.

Topics will include the following:

·         Beyond mAbs: New Challenges for Novel Framework

·         Biological Consequences of HOS (safety, efficacy, PK) and Impact to CQA

·         HOS Development: Process/product development/commercialization/post-approval

·         HOS Emerging and Novel Technologies

·         HOS Fundamentals: Why Structure Matters

·         HOS Protein Therapeutics Discovery, Candidate Selection Engineering

•         Merging Experimental and Computational Approaches to HOS Characterization 

We urge professionals from the following functions to not only attend but to fully engage in these important discussions: Discovery Sciences Process, Product Development Formulation Development Quality Assurance, Quality Control, Regulatory Affairs, Immunology Molecular, Biological Consequences, H/D Exchange and Cell Biology Analytical Development Manufacturing Sciences Clinical Pharmacology.

 






more Calendar

7/15/2019 » 7/16/2019
CMC Strategy Forum North America Summer 2019

9/17/2019 » 9/20/2019
Mass Spec 2019

9/29/2019 » 10/2/2019
CE Pharm 2019

Featured Members
Membership Software Powered by YourMembership  ::  Legal